Karyopharm Therapeutics Inc. (KPTI) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
KPTI Q4 2025: R&D Spend Falls 12% as Myelofibrosis Data Readout Nears
June 15, 2026
-
Karyopharm (KPTI) Q4 2025: 43% Operating Loss Improvement Sets Stage for March Myelofibrosis Data Catalyst
June 15, 2026
-
Karyopharm (KPTI) Q1 2026: Sentry OS Hazard Ratio at 0.43 Signals Potential Myelofibrosis Paradigm Shift
May 14, 2026
-
KPTI Q3 2025: Sentry Phase 3 Readout Drives $1B Myelofibrosis Ambition
November 03, 2025
-
KPTI Q2 2025: Sentry Trial Nears Completion, $1B Myelofibrosis Opportunity Takes Shape
August 11, 2025